OBJECTIVE： To observe the effects of Ehong tablets on hemorheology and related indexes of thrombosis in acute blood stasis model rats. METHODS： Totally 72 male SD rats were randomly divided into blank group， model group， Naoxintong capsules group （0.8 g/kg） and Ehong tablets low-dose， medium-dose and high-dose groups （0.375， 0.75， 1.5 g/kg）， with 12 rats in each group. Administration groups were given relevant medicine intragastrically； blank group and model group were given constant volume of normal saline intragastrically， once a day， for consecutive 7 d. Except for blank group， other groups were given adrenaline hydrochloride （0.06 mg/kg） subcutaneously 1 h after last medication， 2 h later were irritated with cold water for 3 min， and then given same dose of adrenaline hydrochloride subcutaneously again 2 h later to induce acute blood stasis model. Twenty hours after fasting without water fasting， the behaviors of rats were observed， whole blood viscosity （high， medium and low shear） and serum contents of TXB2 and 6-k-PGF1a were detected. RESULTS： The rats in the normal group had normal diet， good mental and active state. The model group suffered from loss of appetite， depression and activity decreasing， etc.； whole blood viscosity （high， medium and low shear） and serum contents of TXB2 were increased significantly， while serum content of 6-k-PGF1a was decreased significantly， compared with blank group， with statistical significance （P＜0.01）. Compared with model group， above symptoms of rats were improved to different extents in administration groups. The whole blood viscosity （high， medium and low shear） and serum contents of TXB2 were decreased significantly in Naoxintong capsules group， Ehong tablets medium-dose and high-dose groups， while serum contents of 6-k-PGF1a was increased significantly， with statistical significance （P＜0.05 or P＜0.01）. CONCLUSIONS： Ehong tablets can reduce blood viscosity and improve blood stasis symptoms to certain extent， the effects of which may be associated with down-regulating serum content of TXB2 and up-regulating serum content of 6-k-PGF1a.